Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 15401 - 15425 of 15824 in total
MUL001 is live attenuated strain of Salmonella typhimurium being investigated for the treatment of schwannomas.
Investigational
LB-P8 is an investigational live biotherapeutic product consisting of a single bacterial strain (Leuconostoc citreum).
Investigational
SNP-ACTH (1-39) is a synthetic porcine Corticotropin (ACTH)
Investigational
TTX-siPDL1 is an siRNA-based modulator of programmed death-ligand 1.
Investigational
mRNA-3745 is a lipid nanoparticle (LNP) encapsulated with nucleoside-modified, codon-optimized mRNAs encoding human glucose 6-phosphatase (G6Pase).
Investigational
AMT-101 is a recombinant human interleukin-10 fusion protein.
Investigational
MB-107 consists of mobilized peripheral blood-derived autologous CD34+ hematopoietic stem cells that are genetically modified to express the IL2RG gene.
Investigational
PBFT02 is a non-replicating recombinant adeno-associated virus serotype 1 vector delivering human GRN gene encoding the protein progranulin.
Investigational
Zelpultide alfa is a recombinant human surfactant protein D.
Investigational
AAV9/MFSD8 is a gene therapy developed by Neurogene Inc. It is an adeno-associated virus serotype 9 (AAV9) vector with an engineered transgene encoding the human CLN7/MFSD8 gene for expression of active human major facilitator superfamily domain containing 8. It was investigated for the treatment of neuronal ceroid lipofuscinosis type 7.
Investigational
CTX110 is an allogeneic CRISPR/Cas9-mediated genetically modified CAR T cell therapy targeting CD19 antigen.
Investigational
SLN500 is a synthetic double-strand small interfering ribonucleic acid (siRNA) oligonucleotide drug directed against C3 messenger RNA
Investigational
ALLO-605 is an allogeneic turbo chimeric antigen receptor (Turbocar) T Cell therapy targeting B Cell maturation antigen (BCMA).
Investigational
Matched Description: … ALLO-605 is an allogeneic turbo chimeric antigen receptor (Turbocar) T Cell therapy targeting B Cell …
AVR-RD-04 is an investigational gene therapy for cystinosis. It consists of autologous CD34+ enriched cells transduced with a lentiviral vector containing RNA resulting in codon-optimized cDNA encoding for functional human cystinosin.
Investigational
MBP134 is a pan-ebolavirus cocktail comprising two broadly neutralizing human antibodies. It is under investigation for the treatment of Sudan ebolavirus (SUDV).
Investigational
EDIT-101 is a recombinant adeno-associated virus pseudotyped with serotype 5 viral capsid encoding CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats associated protein 9) gene editing constructs.
Investigational
The Cellspan Esophageal ImplantTM (CEI) composes of autologous adipose-derived mesenchymal stromal cells (Ad-MSC) seeded onto a polyurethane tubular mesh cell delivery device.
Investigational
ABBV-706 is an antibody-drug conjugate that is anti-SEZ6.[L49156,L49161]
Investigational
HH-009 is a recombinant human IgG4 monoclonal antibody against FGF19 being studied for the treatment of hepatocellular carcinoma.
Investigational
HTPEP-001 is a novel peptide that works to inhibit the activation of transforming growth factor beta (TGF-β). It is being investigated for the treatment of fibrosis.
Investigational
Sacituzumab tirumotecan is a recombinant humanized IgG1 anti-TROP2 monoclonal antibody conjugated to a topoisomerase I inhibitor.
Investigational
Sasanlimab is under investigation in clinical trial NCT06218069 (Immuno-pet Imaging Responses Administered Immune Checkpoint Inhibitor).
Investigational
Ragifilimab is under investigation in clinical trial NCT04225039 (Anti-gitr/anti-pd1/stereotactic Radiosurgery, in Recurrent Glioblastoma).
Investigational
Displaying drugs 15401 - 15425 of 15824 in total